Johnson & Johnson (NYSE:JNJ) Stock Price Down 0% - Here's What Happened

Johnson & Johnson (NYSE:JNJ - Get Free Report) fell 0% on Friday . The stock traded as low as $155.06 and last traded at $155.62. 1,143,948 shares changed hands during trading, a decline of 85% from the average session volume of 7,865,409 shares. The stock had previously closed at $155.66.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Johnson & Johnson Stock Down 0.4 %

The stock's fifty day moving average price is $158.12 and its 200-day moving average price is $154.44. The company has a market capitalization of $373.01 billion, a price-to-earnings ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently modified their holdings of the stock. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $32,000. Finally, Conquis Financial LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.